There is no abstract available.


Article metrics loading...

Loading full text...

Full text loading...


Literature Cited

  1. Roossinck MJ. 1.  2011. The good viruses: viral mutualistic symbioses. Nat. Rev. Microbiol. 9:99–108 [Google Scholar]
  2. Kelly E, Russell SJ. 2.  2007. History of oncolytic viruses: genesis to genetic engineering. Mol. Ther. 15:651–59 [Google Scholar]
  3. Bell J, McFadden G. 3.  2014. Viruses for tumor therapy. Cell Host Microbe 15:260–65 [Google Scholar]
  4. Choi A, O'Leary M, Fong Y, Chen N. 4.  2016. From benchtop to bedside: a review of oncolytic virotherapy. Biomedicines 4:18 [Google Scholar]
  5. Pol J, Kroemer G, Galluzzi L. 5.  2016. First oncolytic virus approved for melanoma immunotherapy. Oncoimmunology 5:e1115641 [Google Scholar]
  6. Kotterman MA, Chalberg TW, Schaffer DV. 6.  2015. Viral vectors for gene therapy: translational and clinical outlook. Annu. Rev. Biomed. Eng 17:63–89 [Google Scholar]
  7. Kastelein JJ, Ross CJ, Hayden MR. 7.  2013. From mutation identification to therapy: discovery and origins of the first approved gene therapy in the Western world. Hum. Gene Ther. 24:472–78 [Google Scholar]
  8. Nathwani AC, Reiss UM, Tuddenham EG, Rosales C, Chowdary P. 8.  et al. 2014. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N. Engl. J. Med. 371:1994–2004 [Google Scholar]
  9. Nayak S, Herzog RW. 9.  2010. Progress and prospects: immune responses to viral vectors. Gene Ther 17:295–304 [Google Scholar]
  10. Schnepp BC, Johnson PR. 10.  2014. Vector-mediated in vivo antibody expression. Microbiol. Spectr. 2:AID–0016-2014 [Google Scholar]
  • Article Type: Introduction
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error